Formulation Development
Medicus Pharma Announces Engagement With Reliant AI to Develop AI-Driven Clinical Data Analytics Platform
Medicus Pharma Ltd. recently announced it has entered into non-binding letter of intent (LOI) with Reliant AI Inc., a decision-intelligence company for the life sciences, specializing in…
Nimbus Therapeutics Announces Completion of Dose Escalation in Phase 1/2 Clinical Trial of a Novel WRN Inhibitor for MSI-H Tumors
Nimbus Therapeutics, LLC recently announced the completion of dose escalation (Part A) in its Phase 1/2 clinical trial of NDI-219216, the company’s investigational non-covalent Werner…
MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 in the Prevention of Chemotherapy-Induced Peripheral Neuropathy
MediciNova, Inc. recently announced the successful completion of patient enrollment in the randomized, placebo-controlled Phase 2 clinical trial, the OXTOX study (Oxaliplatin Neurotoxicity study in…
Brainomix AI Technology Reveals Efficacy of Novel Neuroprotective Drug Candidate in Severe Acute Ischemic Stroke Patients
Brainomix recently announced results from its partnership with Argenica Therapeutics for imaging and clinical data analysis of the Phase II trial evaluating ARG-007, a neuroprotective…
PADCEV Plus Keytruda Significantly Improves Survival for Patients With Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
Astellas Pharma Inc. and Pfizer Inc. recently announced positive topline results from an interim analysis of the Phase 3 EV-304 clinical trial (also known as…
Affibody Accelerates Phase 1 Study with ABY-271 Following Initial Patient Data
Affibody AB recently announced the Trial Review Committee (TRC) has recommended to advance the Phase I clinical study with the Radioligand Therapy (RLT) candidate ABY-271…
Lindus Health & Quotient Sciences Partner to Accelerate Drug Development From First-in-Human to Pivotal Trials
Lindus Health and Quotient Sciences have announced a strategic partnership to enable innovative biotech and pharma sponsors with enhanced patient recruitment for Phase I-IIa clinical studies and…
Bicycle Therapeutics Establishes Multiple Strategic Partnerships to Create End-to-End Supply Chain to Support its Wholly Owned Radiopharmaceutical Pipeline
Bicycle Therapeutics plc (NASDAQ: BCYC) recently announced it has entered into a 15-year contract including an option to renew with the UK Nuclear Decommissioning Authority (NDA)…
Peapod Bio & Enamine Announce Strategic Collaboration
Peapod Bio Inc. recently announced a strategic collaboration with Enamine, enabling Peapod Bio to offer its clients fully integrated screening campaigns with access to Enamine’s…
Medicus Pharma Completes Enrollment of 90 Patients for Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin
Medicus Pharma Ltd. recently announced its Phase 2 clinical study (SKNJCT-003) evaluating safety and efficacy of Doxorubicin Microneedle Array (D-MNA) to non-invasively treat nodular basal…
FDA Approves First-in-Class, Single-dose, Oral Antibiotic for the Treatment of Uncomplicated Urogenital Gonorrhea in Adults & Adolescents
Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. recently announced the US FDA has approved NUZOLVENCE (zoliflodacin) for oral suspension, a first-in-class, single-dose oral medication…
Nanexa & Moderna Enter License & Option Agreement for the Development of PharmaShell®-Based Products
Nanexa AB recently announced the signing of a license and option agreement with Moderna, Inc. Under the agreement, Moderna receives a license to use Nanexa’s…
2026 COMPANY PROFILES & CAPABILITIES
For each participating company, this section presents a detailed summary highlighting their core technologies, capabilities, technologies, and services.
PURIFICATION STRATEGIES - Purification at Scale: Overcoming Chromatography Challenges for Advanced Modalities
William Sanders, PhD, explores the real-world challenges of scaling chromatography and highlights how contract development and manufacturing organizations (CDMOs) can help partners overcome them.
DRUG DEVELOPMENT - Common CMC Pitfalls in Orphan Drug Development
Hibreniguss Terefe, PhD, says although the unique challenges of orphan drug development are amplified by compressed timelines and limited patient populations, common pitfalls also serve as cautionary tales for other areas of drug development.
3D PRINTING - The Future of 3D Printing in Pharma: Aprecia’s Vision for Transformative Medicine
Kyle Smith, MBA, explains how his company, a pioneer in pharmaceutical 3D printing, has a vision for distributed, patient-centric manufacturing that could re-shape the future of medicine.
ORAL SUSPENSIONS - A New Standard in Oral Suspensions: Leveraging Novel Excipients for FDA Approval
Mary Schuster introduces a new approach to perfecting oral suspension formulations, which is centered on the strategic use of a “novel” synthetic functional excipient, magnesium aluminometasilicate (MAS).
DRUG DELIVERY - PharmaShell®: Enabling Once-Monthly Therapeutics With Atomic Precision Coatings
Anders Johansson, PhD, Polla Rouf, PhD, and Joel Hellrup, PhD, review an innovative drug delivery system that uses nanometer-thin, inorganic coatings to turn short-acting drugs into long-acting injectables.
INJECTABLE DEVICES - Delivering Tomorrow’s Injectables to Patients Today: Responding to a New Era of Demand With Purpose-Built Capabilities
Tommy Schornak examines how evolving therapeutic modalities, delivery systems, and regulatory expectations are reshaping the fill finish landscape.
PLATFORM TECHNOLOGY - Developing Innovative Solutions to One of the Top Public Health Threats: Antibacterial Resistance
Jennifer Schneider, PhD, believes immunotherapy holds the potential to revolutionize the treatment of “hard to treat,” chronic, and often recalcitrant infections.
